These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31340801)

  • 1. RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
    Yang Z; Fu B; Zhou L; Xu J; Hao P; Fang Z
    BMC Urol; 2019 Jul; 19(1):69. PubMed ID: 31340801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
    Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
    JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea.
    Kim GK; Jo YH; Lee J; Han HH; Ham WS; Jang WS; Heo JE
    Investig Clin Urol; 2024 Sep; 65(5):435-441. PubMed ID: 39249915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
    Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
    J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Steinberg RL; Thomas LJ; Brooks N; Mott SL; Vitale A; Crump T; Rao MY; Daniels MJ; Wang J; Nagaraju S; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
    J Urol; 2020 May; 203(5):902-909. PubMed ID: 31821066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
    Cao M; Ma CK; Ma J; Chen HG; Xue W
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):385-7. PubMed ID: 21875472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
    Zhao LP; Xue C; Zhang JW; Hu ZH; Zhao YY; Zhang J; Huang Y; Zhao HY; Zhang L
    Chin J Cancer; 2012 Oct; 31(10):476-83. PubMed ID: 22692073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
    Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
    Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
    Matsumura N; Nakamura Y; Kohjimoto Y; Nishizawa S; Kikkawa K; Iba A; Kodama Y; Hara I
    Int J Urol; 2017 Mar; 24(3):230-235. PubMed ID: 28066957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
    Kim M; Ku JH; Kwak C; Kim HH; Lee E; Keam B; Kim TM; Heo DS; Lee SH; Moon KC
    PLoS One; 2015; 10(7):e0133371. PubMed ID: 26200905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
    Xie H; Jiang W; Jiang J; Wang Y; Kim R; Liu X; Liu X
    Cancer; 2013 Jan; 119(1):173-81. PubMed ID: 22736490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
    Cockerill PA; Knoedler JJ; Frank I; Tarrell R; Karnes RJ
    BJU Int; 2016 Mar; 117(3):456-62. PubMed ID: 25682834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
    Nie X; Cheng G; Ai B; Zhang S
    Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
    Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.